Was the Kymera Therapeutics (KYMR) director’s share sale under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan dated September 17, 2025. Such plans allow insiders to pre-schedule trades in advance, helping separate trading activity from day-to-day discretionary decisions.

What is the net share effect of Pamela Esposito’s Kymera Therapeutics (KYMR) transactions?

The director exercised options for 2,500 Kymera shares and sold 2,500 shares, resulting in a net reported sale of 2,500 shares in the transaction summary. This reflects more shares sold than acquired when considering open-market activity versus the option exercise.

Director at Kymera Therapeutics (KYMR) sells 2,500 shares under trading plan

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Kymera Therapeutics director Pamela Esposito reported option exercises and share sales. She exercised stock options for 2,500 shares of common stock at $49.10 per share through a derivative conversion, from a fully vested and exercisable option grant.

On the same date, she sold 1,900 common shares at a weighted average price of $87.0579 and 600 shares at $88.10, in open-market transactions. According to the disclosure, these sales were executed under a Rule 10b5-1 trading plan dated September 17, 2025, which pre-arranges trades in advance.

Insider Trade Summary

Net Seller: 2,500 shares ($218,270)

Net Sell 4 txns

Insider Esposito Pamela

Role Director

Sold 2,500 shs ($218K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,500	$0.00	--
Exercise	Common Stock	2,500	$49.10	$123K
Sale	Common Stock	1,900	$87.0579	$165K
Sale	Common Stock	600	$88.10	$53K

Holdings After Transaction: Stock Option (Right to Buy) — 2,500 shares (Direct); Common Stock — 2,500 shares (Direct)

Footnotes (1)

These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.52 to $87.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.58 to $88.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The shares underlying this stock option are fully vested and exercisable.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/20/2026 - 05:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Esposito Pamela

(Last)

(First)

(Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN

02472

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/20/2026		M⁽¹⁾		2,500	A	$49.1	2,500	D
Common Stock	02/20/2026		S⁽¹⁾		1,900	D	$87.0579⁽²⁾	600	D
Common Stock	02/20/2026		S⁽¹⁾		600	D	$88.1⁽³⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$49.1	02/20/2026		M⁽¹⁾			2,500	⁽⁴⁾	06/15/2031	Common Stock	2,500	$0	2,500	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.52 to $87.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.58 to $88.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Kymera Therapeutics (KYMR) disclose for Pamela Esposito?

Kymera Therapeutics reported that director Pamela Esposito exercised options for 2,500 common shares, then sold 2,500 common shares in open-market transactions. The trades combined a derivative option exercise with subsequent stock sales on the same date under a pre-arranged Rule 10b5-1 trading plan.

How many Kymera Therapeutics (KYMR) shares did the director sell and at what prices?

Pamela Esposito sold 1,900 Kymera common shares at a weighted average price of $87.0579 and 600 shares at $88.10. The filing notes both blocks were executed through multiple trades within stated price ranges on the same transaction date.

What stock options did Pamela Esposito exercise at Kymera Therapeutics (KYMR)?

She exercised a fully vested and exercisable stock option covering 2,500 Kymera common shares at an exercise price of $49.10 per share. This option exercise converted a derivative right to buy into directly held common stock before the subsequent sales were executed.

What do the weighted average prices mean in the Kymera Therapeutics (KYMR) Form 4?

The filing explains the reported prices are weighted averages from multiple trades within price ranges of $86.52–$87.49 and $87.58–$88.40. The director has committed to provide detailed per-trade prices and share counts upon request to the company, shareholders, or regulators.